Upstream Bio, Inc.

UPB

Held by 1 specialist biotech fund

Share on X

Fund Holdings

OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 5,693,589Value: $154.6M

# Signal Note: OrbiMed Initiates $154.6M Position in Upstream Bio OrbiMed's entry into UPB signals conviction in the company's pipeline, likely centered on its lead program in autoimmune/inflammatory disease. The $155M position size from a premier healthcare allocator suggests confidence in near-term catalysts, potentially including clinical data readouts or partnership announcements within 12-24 months. Monitor upcoming trial updates as key near-term newsflow that could validate this thesis.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS1 fund RNA1 fund BIOA1 fund IRON1 fund ANRO1 fund FOLD1 fund BCAX1 fund ARGX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: